Stock ATAI ATAI LIFE SCIENCES N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.84 USD -1.60% Intraday chart for Atai Life Sciences N.V. -3.66% +30.50%
Apr. 24 Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression CI
Apr. 17 Clarify Pharma to change name to File Forge Technology AN

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ATAI LIFE SCIENCES N.V. Stock Atai Life Sciences N.V.
+30.50% 308M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
B-
LONZA GROUP AG Stock Lonza Group AG
+47.41% 40.57B
A
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
C+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ATAI Stock
  4. Ratings Atai Life Sciences N.V.